# Chronolife

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chronolife-s-a-s

- Industry: Healthcare IT
- Headquarters: Paris, France
- Website: www.chronolife.net
- Total disclosed funding: $13M
- Latest round: Series B (Oct 17, 2019)
- Investors on record: 3

## About

Chronolife, S.A.S. is a Paris-based digital health company specializing in innovative solutions for continuous physiological monitoring through their Keesense device integrated into smart textiles, enhancing health tracking capabilities for various users.Chronolife, founded in 2015 in Paris, France, focuses on developing digital health services through its Keesense solution. The company has engaged in 3 deals, with its most recent funding round being a Series B in October 2019, raising EUR 6.877 mn from investors including ADRÉA Mutual, Celeste Management, and iBionext. The current CEO is Franck Le Meur.Chronolife specializes in digital health services through its core product, the Keesense solution, which is a multiparametric connected medical device for continuous monitoring of physiological parameters. The Keesense device is designed to be integrated into smart textiles, such as connected t-shirts, enabling real-time tracking of various health indicators, including electrocardiogram (ECG), respiratory rates, body temperature, and physical activity levels. These wearables are particularly beneficial for individuals in home healthcare settings, as well as for high-risk professions and elite athletes, facilitating remote monitoring of health conditions. The company's solutions are sold across multiple markets, including France, Germany, Switzerland, Austria, Denmark, Finland, Norway, and Sweden, addressing the needs of patients with chronic conditions, isolated workers, and individuals requiring health monitoring in high-stress environments like defense, healthcare, and sports.Chronolife generated a revenue of EUR 153,585.30 in the most recent year, 2023, with an EBITDA of EUR -2,885,207.60.Chronolife plans to leverage the EUR 6.88 mn raised in Series B funding in December 2019 to enhance its product offerings and expand its market presence. The company aims to develop new features for the Keesense solution and explore additional markets beyond its current reach, targeting expansion in Europe and potentially entering Asian markets by 2024.

## Funding rounds

- Series B, Oct 17, 2019, $7.7M — iBionext, Celeste Management, ADRÉA Mutual
- Series A, Apr 23, 2018, $5M — iBionext

## Investors

- iBionext (https://capitalatlas.ai/funds/ibionext) — Series A, Series B
- Celeste Management — Series B
- ADRÉA Mutual — Series B